evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,973 questions · 3,072 findings · 410 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 559 · 18.2%GRADE not reported 143 · 4.7%Very low 654 · 21.3%Low 833 · 27.1%Moderate 683 · 22.2%High 200 · 6.5%

Benralizumab 10 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg probably leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).

1 finding from 1 review